Abstract
In this review paper we aim at giving a detailed overview on our research work devoted to the design of gold-based anticancer agents. In particular, during the last decade, we have been developing some gold(III)-dithiocarbamato derivates showing outstanding in vitro and in vivo antitumor properties and reduced, or even no, systemic and renal toxicity, compared to the reference clinically-established anticancer drug cisplatin. Starting from the rationale behind our investigations, we here summarize the results achieved so far, focusing on the latest in-depth mechanistic studies that have recently provided insights into their mechanism of action, thus opening up new prospects for further pharmacological testing and, hopefully, to enter clinical trials.
Keywords: Anticancer drug, Dithiocarbamate, Gold compounds, Metallodrug, Nephrotoxicity, Proteasome inhibitor, Reactive oxygen species (ROS), Thioredoxin reductase (TrxR)
Anti-Cancer Agents in Medicinal Chemistry
Title: Latest Insights into the Anticancer Activity of Gold(III)-Dithiocarbamato Complexes
Volume: 10 Issue: 4
Author(s): Luca Ronconi, Donatella Aldinucci, Q. Ping Dou and Dolores Fregona
Affiliation:
Keywords: Anticancer drug, Dithiocarbamate, Gold compounds, Metallodrug, Nephrotoxicity, Proteasome inhibitor, Reactive oxygen species (ROS), Thioredoxin reductase (TrxR)
Abstract: In this review paper we aim at giving a detailed overview on our research work devoted to the design of gold-based anticancer agents. In particular, during the last decade, we have been developing some gold(III)-dithiocarbamato derivates showing outstanding in vitro and in vivo antitumor properties and reduced, or even no, systemic and renal toxicity, compared to the reference clinically-established anticancer drug cisplatin. Starting from the rationale behind our investigations, we here summarize the results achieved so far, focusing on the latest in-depth mechanistic studies that have recently provided insights into their mechanism of action, thus opening up new prospects for further pharmacological testing and, hopefully, to enter clinical trials.
Export Options
About this article
Cite this article as:
Ronconi Luca, Aldinucci Donatella, Ping Dou Q. and Fregona Dolores, Latest Insights into the Anticancer Activity of Gold(III)-Dithiocarbamato Complexes, Anti-Cancer Agents in Medicinal Chemistry 2010; 10 (4) . https://dx.doi.org/10.2174/187152010791162298
DOI https://dx.doi.org/10.2174/187152010791162298 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of mTOR Signaling in Tumor Cell Motility, Invasion and Metastasis
Current Protein & Peptide Science Prediction and Early Evaluation of Anticancer Therapy Response: From Imaging of Drug Efflux Pumps to Targeted Therapy Response
Current Medicinal Chemistry Tetraplex Binding Molecules as Anti-Cancer Agents
Recent Patents on Anti-Cancer Drug Discovery Editorial
Current Medical Imaging Rho GTPases: Promising Cellular Targets for Novel Anticancer Drugs
Current Cancer Drug Targets Novel Ideas of Gene Therapy for Atherosclerosis: Modulation of Cellular Signal Transduction of TGF-β Family
Current Pharmaceutical Design Pathological and Therapeutic Aspects of Long Noncoding RNAs in Osteosarcoma
Anti-Cancer Agents in Medicinal Chemistry Nanosponges Encapsulated Phytochemicals for Targeting Cancer: A Review
Current Drug Targets MDMA Administration and Heat Shock Proteins Response: Foreseeing a Molecular Link
Current Pharmaceutical Biotechnology The potential for circulating microRNAs in the diagnosis of myocardial infarction: a novel approach to disease diagnosis and treatment
Current Pharmaceutical Design Radionuclides Used in Nuclear Medicine Therapy – From Production to Dosimetry
Current Medical Imaging Targeting RhoA/Rho Kinase and p21-Activated Kinase Signaling to Prevent Cancer Development and Progression
Recent Patents on Anti-Cancer Drug Discovery The Potential Anti-Tumorigenic and Anti-Metastatic Side of the Proprotein Convertases Inhibitors
Recent Patents on Anti-Cancer Drug Discovery Gallic Acid Improved Amytryptiline Effect in Neuropathic Pain Induced by Partial Sciatic Nerve Ligation (PSNL) in Rats
The Natural Products Journal Anti-Angiogenic Peptides for Cancer Therapeutics
Current Pharmaceutical Biotechnology CXCL12-CXCR4 Axis in Angiogenesis, Metastasis and Stem Cell Mobilization
Current Pharmaceutical Design Role of Microtubules Network in CYP Genes Expression
Current Drug Metabolism Lumiflavin Enhances the Effects of Ionising Radiation on Ovarian Cancer Stem-Like Cells by Inhibiting Autophagy
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in Enone and NO-Releasing Derivatives of Oleanolic Acid with Anti-cancer Activity
Mini-Reviews in Organic Chemistry PEDF & Stem Cells: Niche vs. Nurture
Current Drug Delivery